arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT US Healthcare and Life Sciences Conference 2015

New York |
Speakers include:
Dr Troyen  Brennan

Dr Troyen Brennan

CVS Health

Christi  Shaw

Christi Shaw

Lilly Bio-Medicines

Geno  Germano

Geno Germano

Pfizer

Overview

EMBRACING CHANGE, FOSTERING GROWTH

Click here to view photo gallery from the 2015 conference

The fourth annual FT US Healthcare and Life Sciences Conference: Embracing Change, Fostering Growth, brought together the industry’s foremost thinkers and leaders to discuss the strategies and approaches they are taking to tackle challenges - from pricing to cyber threats - and to embrace opportunities for growth in this dynamic and innovative space.

The healthcare and life sciences industry are facing a time of both tumultuous change and momentous opportunity. In the US, healthcare reform has reached a new level of maturity and is beginning to transform the landscape of the industry for payers, providers and patients; The biotechnology industry is on the rise, and has been leading the way in deal making and important drug launches. Meanwhile the industry is gradually waking up to the opportunities and disruptive threats of digital health as the wearable craze takes hold, health apps proliferate and big data becomes a reality. With so much change and innovation underway, are we now at the cusp of a major transformation of the healthcare system? What does the future hold?

TOPICS DISCUSSED:

  • Growth and transformation strategies at the intersection of change: M&A and beyond
  • Aging, disease and the secrets of longevity
  • The potential and perils of digital health and cyber security
  • Pricing and reimbursement: surviving and thriving in a value based world
fallback
fallback Add to my Calendar 05/06/2015 08:00:0005/06/2015 16:45:00trueFT US Healthcare and Life Sciences Conference 2015EMBRACING CHANGE, FOSTERING GROWTHClick here to view photo gallery from the 2015 conferenceThe fourth annual FT US Healthcare and Life Sciences Conference: Embracing Change, Fostering Growth, brought together the industry’s foremost thinkers and leaders to discuss the strategies and approaches they are taking to tackle challenges - from pricing to cyber threats - and to embrace opportunities for growth in this dynamic and innovative space.The healthcare and life sciences industry are facing a time of both tumultuous change and momentous opportunity. In the US, healthcare reform has reached a new level of maturity and is beginning to transform the landscape of the industry for payers, providers and patients; The biotechnology industry is on the rise, and has been leading the way in deal making and important drug launches. Meanwhile the industry is gradually waking up to the opportunities and disruptive threats of digital health as the wearable craze takes hold, health apps proliferate and big data becomes a reality. With so much change and innovation underway, are we now at the cusp of a major transformation of the healthcare system? What does the future hold?TOPICS DISCUSSED:Growth and transformation strategies at the intersection of change: M&A and beyondAging, disease and the secrets of longevityThe potential and perils of digital health and cyber securityPricing and reimbursement: surviving and thriving in a value based worldFT-US-Healthcare-and-Life-Sciences-Conference-20159765b3e222f9da4f4facfbab571c2b6dMM/DD/YYYY

Speakers (27)

Dr Troyen  Brennan

Dr Troyen Brennan

Chief Medical Officer
CVS Health

Troyen Brennan is Executive Vice President and Chief Medical Officer of CVS Health. In this role, Dr Brennan has responsibility for CVS Health’s health care and wellness programs.

Previously, he was Chief Medical Officer of Aetna Inc. Prior to that, he served as President of the Brigham and Women's Physicians Organization.  In his academic work, he was Professor of Medicine at Harvard Medical School and Professor of Law and Public Health at Harvard School of Public Health.

Dr Brennan received  MD. and M.P.H. degrees from Yale Medical School and  J.D. degree from Yale Law School.  He completed his internship and residency in internal medicine at Massachusetts General Hospital.  He is a member of the Institute of Medicine of the National Academy of Sciences.

Christi  Shaw

Christi Shaw

President
Lilly Bio-Medicines

Christi Shaw re-joined Eli Lilly and Company in April 2017 as Senior Vice President and President of Lilly Bio-Medicines. Leading Lilly’s broadest therapeutic portfolio, she oversees late-stage clinical development and commercialization for the company’s leading positions in Immunology, Pain and Alzheimer’s disease, some of Lilly’s most significant opportunities to make life better for patients. She also leads commercial responsibilities in the world’s largest markets for Lilly medicines in neuroscience, men’s health and osteoporosis.

After beginning her career at Lilly in 1989, Ms Shaw has held positions of increasing influence and authority across the bio-pharmaceutical industry over three decades, including leadership positions at Lilly, Johnson & Johnson and Novartis, where she most recently served as US Country Head, President of Novartis Corporation and President of Novartis Pharmaceuticals Corporation. Her leadership spans a broad range of therapeutic areas, including oncology, cardiovascular and respiratory, dermatology, immunology, neuroscience, ophthalmology and medical devices.

Ms Shaw has served on the boards of the Biotechnology Industry Organization (BIO), the Healthcare Leadership Council and the Young Women’s Leadership Network. In May 2016, she was presented with Eye for Pharma’s prestigious “Lifetime Achievement Award” for her industry thought-leadership and dedication to the needs of patients. PharmaVOICE also named Ms Shaw to its “100 Most Inspiring People” list in 2016, and Diversity Journal included her in its list of “Women Worth Watching.” Ms Shaw has spoken at leading industry conferences on the future of healthcare, driving innovation to support better patient outcomes and encouraging a diverse and inclusive culture. In addition, her perspectives have been featured in Working Mother and Life Science Leader.

In 2017, Ms Shaw founded the More Moments More Memories Foundation to assist people with cancer and their caregiver. A proud native of Iowa, Shaw and her sisters own and manage a number of local farms, advancing innovative green methods to promote sustainability, conservation and forest preservation, while supporting future independent farmers. She earned an MBA from the University of Wisconsin and a BBA from Iowa State University. 

Geno  Germano

Geno Germano

Group President, Global Innovative Pharma Business
Pfizer

Geno Germano is Group President of Pfizer’s Global Innovative Pharma Business, the company’s operating unit focused on development, registration and commercialization of novel, value creating medicines that significantly improve patients’ lives. In this role, Mr Germano leads a growing global business with market-leading medicines and a robust pipeline in several therapeutic areas including inflammation, cardiovascular and metabolic disease, neuroscience and pain and rare diseases. Additionally, Mr Germano is Co-Chair of the Portfolio Strategy and Investment Committee which focuses on maximizing the return on research and development investment across the Pfizer Inc. portfolio. Mr Germano is a member of Pfizer’s Executive Leadership Team.

Previously, Mr Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units. With more than 25 years of international experience in the pharmaceutical industry, Mr Germano joined Pfizer from Wyeth Pharmaceuticals, where he most recently served as President of the US and Pharmaceutical business units and was responsible for the US Pharmaceuticals, Biologics and Vaccines businesses. Mr Germano also held various commercial development and strategy positions at Johnson & Johnson companies.
Mr Germano is a member of the Board of the Biotechnology Industry Organization. He received his Bachelor of Science degree in Pharmacy from the Albany College of Pharmacy where he currently serves on the Board of Trustees.

Paul  Hudson

Paul Hudson

President, AstraZeneca US and Executive Vice President, North America
AstraZeneca

Paul Hudson is responsible for leading AstraZeneca’s commercial operations in North America and represents the region as a member of the Senior Executive Team. In this capacity he is accountable for driving growth and maximizing contribution of North America to AstraZeneca’s global business.

Prior to his role in North America, Mr Hudson served as Representative Director and President of AstraZeneca K. K., the Japanese subsidiary of AstraZeneca PLC. He has served as a Standing Board Member of JPMA (Japan Pharmaceuticals Manufacturers Association) and EFPIA (European Federation of Pharmaceutical Industries and Associations) in Japan.

Previously Mr Hudson was President of AstraZeneca’s business in Spain. He joined AstraZeneca in 2006 as Vice President and Primary Care Director, UK.

Before AstraZeneca, Mr Hudson worked for Schering Plough, where he held roles of increasing seniority, including leading biologics global marketing, based in the US. He began his career at GSK UK and Sanofi-Synthelabo UK with roles in sales and marketing.

Mr Hudson serves on the Board of Directors of BIO, is a Member of the Healthcare Leadership Council and a Member of the Value & Science Driven Health Care Roundtable of the Institute of Medicine. He has a degree in Economics from Manchester Metropolitan University and a Diploma in Marketing from Chartered Institute of Marketing, UK.

Peter  Bach

Peter Bach

Director, Center for Health Policy and Outcomes
Memorial Sloan Kettering Cancer Center

Dr Peter Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. He is the Director, and currently holds the titles of Member in the Department of Epidemiology and Biostatistics and Attending Physician in the Department of Medicine at Memorial Sloan Kettering. He has also been a Senior Scholar at the International Agency for Research on Cancer since 2008.

Dr Bach is a member of the Institute of Medicine’s Board on Health Care Services and National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance; he is also the Chair of the Center for Medicare and Medicaid Services Technical Expert Panel, which works to develop quality measures for PPS-exempt cancer hospitals. He has been inducted into the American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He also serves on the Board of Advisors of the University of Michigan Cancer Center and on the World Economic Forum, and is a member of the Clinton Global Initiative. Previously, Dr Bach was a member of the Institute of Medicine’s Committee on Geographic Variations and the Chair of a multi-society evidence-based guideline development committee on lung cancer screening. He also served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006

Dr Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar.

Brian Cincera

Brian Cincera

Vice President, Global Information Security
Pfizer
David  Cordani

David Cordani

President and CEO
Cigna Corporation

David Cordani became President and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company.  He is a prominent voice addressing key health service challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements, and partnering with physicians to focus on wellness, and improving clinical quality.

With operations and capabilities in more than 30 countries, Mr Cordani leads Cigna's more than 35,000 employees in improving the health, well-being and sense of security of more than 80 million customer relationships.

Cordani has been with Cigna for 23 years; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.

Prior to joining Cigna, Mr Cordani was with Coopers & Lybrand. He actively works with March of Dimes, The Juvenile Diabetes Research Foundation, the Achilles International Freedom Team of Wounded Veterans and is a charter member of ChildObesity180.  

Mr Cordani earned a Bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.    

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Helen Darling

Helen Darling

Strategic Adviser, Former President and CEO
National Business Group on Health

Helen Darling is Strategic Advisor at the National Business Group on Health (NBGH). From 2001 to May 1, 2014, she was President and CEO of NBGH, a national non-profit, membership organization devoted to providing practical solutions to its over 400 employer-members' most important health care problems and representing large employers' perspective on national health policy issues. Including 67 of the Fortune 100, its members provide benefits to over 50 million employees, retirees and dependents. Ms Darling is also Chair, Board of Directors of the National Quality Forum, Director of the Reagan-Udall Foundation, Member of the Medical Advisory Panel for Blue Cross Blue Shield and the Institute of Medicine’s Roundtable on Value and Science-Driven Health Care. Previously, Ms Darling served as practice leader at Watson Wyatt; directed health care purchasing at Xerox Corporation; was a principal at William W. Mercer; and senior health LA for the ranking Republican on the Senate Finance Committee.

Walter  de Brouwer

Walter de Brouwer

Founder and CEO
Scanadu

Walter de Brouwer is the Founder and CEO of Scanadu, a NASA Ames Research-based company with the mission of putting the diagnostic power of a hospital in the hands of the consumer, modelled after the fictional tricorder once imagined in Star Trek. Mr de Brouwer is a Belgian-born technology entrepreneur, who started Scanadu in 2010 after a life-altering family emergency, with the goal of building a suite of smartphone-based medical tools that reimagine access to healthcare for the people. Prior to Scanadu, Mr de Brouwer ran One Laptop Per Child Europe and founded Starlab.  His companies were involved in two IPOs and the merger of Eunet with Qwest Communications (now CenturyLink).

Aubrey  de Grey

Aubrey de Grey

Vice President of New Technology Discovery
AgeX Therapeutics

Aubrey de Grey​ is Vice President of New Technology Discovery at AgeX Therapeutics, a subsidiary of BioTime, Inc developing new therapies in the field of biomedical gerontology. He is also the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. Additionally, he is Editor-in-Chief of Rejuvenation Research, a peer-reviewed journal from Mary Ann Liebert publishers focused on intervention in aging. His books include Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime (co-author, 2008, St. Martin’s Griffin) and The Mitochondrial Free Radical Theory of Aging (1999, R.J Landes), as well as numerous articles in peer-reviewed scientific journals. He has been interviewed by a variety of media outlets including The Economist, CBS’ “60 Minutes,” The New York Times, The Washington Post, Fortune, TIME and “The Colbert Report”. He received his BA in Computer Science and PhD in Biology from the University of Cambridge.

Pierre-Alexandre  Fournier

Pierre-Alexandre Fournier

Co-founder and CEO
Hexoskin

Pierre-Alexandre Fournier is Co-Founder and CEO of Hexoskin, a wearable health technology company based in Montreal that focuses on smart clothing design and intelligent algorithms for health management. Hexoskin was founded in 2006, and launched in 2013 the first iPhone and Android compatible smart clothing for health monitoring.Prior to co-founding Hexoskin, Mr Fournier worked for Bell Canada, fabless semiconductor company, Octasic, and then for many other innovative companies as a research and development consultant specialized in speech and video processing, data mining and machine learning. His work at Hexoskin involves the development of new wearable sensors for remote health monitoring during space missions, physiological modelling for health analysis, and smart clothing design. Mr Fournier is also the Co-Founder of Quantified Self Montreal, a group that promotes self-knowledge through numbers.

Felix Frueh

Felix Frueh

Chief Scientific Officer
Human Longevity

Felix Frueh is a respected thought leader in personalized medicine with seventeen years of R&D, management and policy experience. As Chief Scientific Officer, Dr Frueh leads all genomic operations including non-clinical microbiome testing, high throughput and next generation genomic sequencing. Dr Frueh is also instrumental in guiding HLI’s collaborations and partnerships with the pharmaceutical and diagnostic industry.

Prior to joining HLI, Dr Frueh was Executive Partner at Opus Three LLC, a life sciences consulting firm advising pharmaceutical and diagnostic companies on scientific, regulatory, and reimbursement strategies for medical products in the personalized health care space. He was an Entrepreneur-in-Residence at Third Rock Ventures, a Boston-based venture capital firm, where he provided scientific and strategic input for the formation of new and the advancement of existing portfolio companies. Before joining Third Rock, Dr Frueh was President of the Medco Research Institute, leading Medco’s real-world, health economics and outcomes research-oriented initiatives and collaborations after having formed Medco’s personalized medicine research and development organization. Before joining Medco, Dr Frueh was the first Associate Director for Genomics at the US FDA, where he built and led the core genomics review team in CDER, and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG).Dr Frueh is the recipient of numerous awards, including the FDA Commissioner’s Special Citation. He serves on the board of the Personalized Medicine Coalition and is also a board member at Enterome Biosciences. Dr Frueh was a postdoctoral fellow at Stanford University and the University of Basel in Switzerland, where he also received his PhD in biochemistry (magna cum laude).

Malay  Gandhi

Malay Gandhi

Managing Director
Rock Health

Malay Gandhi serves as Rock Health’s Managing Director, leading the organization and working closely with portfolio companies. He joined Rock Health in 2012 after nearly eight years with Deloitte Consulting’s healthcare practice. Malay earned a Masters concentrated in Health Policy and Management from the University of Pittsburgh and a BS from West Virginia University. His work in digital health has been cited in the The New York Times, Financial Times, CNBC, NPR, USA Today, Inc., and The Information.

Dr Todd Hobbs

Dr Todd Hobbs

Chief Medical Officer, North America
Novo Nordisk

Dr Todd Hobbs is the Chief Medical Officer for North America at Novo Nordisk, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system and healthcare professionals in the United States and Canada.

Dr Hobbs provides overall medical guidance to Novo Nordisk’s diabetes- and obesity-related projects. He provides input into the clinical development and life-cycle management strategies for diabetes and obesity, as well as medical input into the R&D pipeline. He is involved with the optimization of relationships with top key opinion leaders and medical societies, and provides guidance to and participates in consultant advisory boards and key patient and professional associations and top thought leaders in diabetes.  

Dr Hobbs began his career at Novo Nordisk in 2004 as a Field Medical Scientific Director, then moving to the position of Senior Medical Director, Diabetes, in 2010. He led the Medical Affairs activities for all of Novo Nordisk’s current insulin products and devices, as well as supporting future insulin products through strategic and tactical activities.

Prior to working at Novo Nordisk, Dr Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as Chairman of the Medicine Department for a large Regional Medical Center in Kentucky. During this 10-year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.  

Dr Hobbs has a unique perspective on and personal dedication to the treatment of diabetes: his own experience with the disease began more than 25 years ago when he was diagnosed with type 1 diabetes. His passion for defeating the disease intensified even more with the diagnosis of one of his sons with the same condition at the age of five.

Dr Rodney Hochman

Dr Rodney Hochman

President and CEO
Providence Health & Services

Dr Rodney Hochman serves as President and CEO of Providence Health & Services, the third largest not-for-profit health system in the US, spanning across Alaska, California, Montana, Oregon and Washington. Under his leadership, Providence is transforming from the fee-for-service system of care to one focused on improving the greater health and well-being of the communities it serves. Through digital innovation, partnerships and new models of care delivery, Providence is improving the consumer experience and creating healthier communities.

Prior to joining Providence, Dr Hochman was President and CEO of Swedish Health Services. During his tenure there, he re-invented the business model from a downtown hospital focus to a regional system of care. Before Swedish, Dr Hochman was Executive Vice President of Sentara Healthcare – a major medical system based in Virginia.

Dr Hochman is a Fellow of the American College of Physicians, a Fellow of the American College of Rheumatology and a member of the American College of Healthcare Executives. His medical background is in rheumatology and internal medicine, having earned his medical degree from Boston University School of Medicine and his Bachelor’s degree from Boston University. He served as an internal medicine clinical fellow at Harvard Medical School and Dartmouth Medical School.

Drew  Holzapfel

Drew Holzapfel

Executive Director
Global CEO Initiative on Alzheimer’s Disease

Drew Holzapfel serves as the Executive Director of The Global CEO Initiative on Alzheimer’s disease, a coalition of leading corporations investing in Alzheimer’s disease research, treatment and care. He is also a Managing Director at High Lantern Group, a healthcare consultancy focused on the intersection of business strategy and public policy. Mr Holzapfel brings 15 years of healthcare experience in government and corporate affairs, sales and marketing in global biotechnology, pharmaceutical and US government organizations to a diverse client base. He has spent nearly a decade working on Alzheimer’s disease in a range of positions. Prior to joining High Lantern Group, Mr Holzapfel was at Pfizer, where he most recently led efforts around the company’s Alzheimer’s program and advanced Alzheimer’s and aging issues through development of commercial strategy and advocacy with international organizations, non-governmental organizations, non-profits and other key stakeholders. During his tenure at Pfizer, Mr Holzapfel launched ReACT (Respect A Caregiver’s Time), a corporate coalition seeking to support employees who are caring for loved ones with age-related, and chronic conditions. Prior to joining Pfizer, Mr Holzapfel managed an external affairs team for a medical device manufacturer, helping drive the company through an initial public offering and the launch of its first product. A former Special Assistant to the Secretary Donna Shalala of the US Department of Health and Human Services, he began his career as a political appointee working in communications at The White House. Mr Holzapfel earned his Bachelor’s degree from Emory University and an MBA from The University of Maryland Smith School of Business.

John  LaMattina

John LaMattina

Senior Partner
PureTech Health

Dr John LaMattina is a Senior Partner at PureTech Health. He serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen Pharmaceuticals, and the Scientific Advisory Board of Trevena Pharmaceuticals. Dr LaMattina also serves on the Board of Trustees of Boston College.

Dr LaMattina is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007.

Dr LaMattina spent 30 years at Pfizer Inc having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.

During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation rheumatoid arthritis and AIDS. Dr LaMattina is the author of numerous scientific publications and holds a number of US patents. In addition, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D and Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image? He is also a contributor to Forbes.com.

Dr LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.

Dr LaMattina graduated cum laude from Boston College in 1971 with a B.S. in Chemistry. He attended the University of New Hampshire working with Professor Robert E. Lyle and received a PhD from UNH in Organic Chemistry in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.

Dame Louise  Makin

Dame Louise Makin

CEO
BTG plc

Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004 and has led the transformation of BTG from an IP commercialisation business into an international specialist healthcare company. Dame Louise is a Non-Executive Director of Intertek Group plc and a Trustee of the Outward Bound Trust.

Previously, from 2001, Dame Louise was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998. Dame Louise was also a Non-Executive Director of Premier Foods plc, between 2006-2012.

Jennifer  Malatesta

Jennifer Malatesta

US Life Sciences Advisory Leader
Deloitte

Jennifer Malatesta-Johnson is the Life Sciences leader for the Risk Advisory Practice for Deloitte & Touche LLP and a principal in the Strategic Risk Services group.  She has over 20 years of diverse experience in pharmaceuticals and other healthcare organizations.   

In her capacity as Leader of the Life Sciences Risk Advisory Practice, she helps leading pharma and health care clients to address their most critical business and technology risks and opportunities.   Her personal areas of industry expertise include reputation risk, corporate threats and managing risks to critical organization life events such as product launches and merger integration.  She is a US leader on strategic risks issues in healthcare.

Ms Malatesta has a Bachelor of Science in Business & Economics from Lehigh and has an MBA from the Wharton School of Business at the University of Pennsylvania. 

Jamey Millar

Jamey Millar

Senior Vice President, Managed Markets and Government Affairs
GlaxoSmithKline

Jamey Millar is Senior Vice President, Managed Markets and Government Affairs at GlaxoSmithKline. Most recently, Mr Millar led GSK’s oncology business unit in the US. He joined GSK in 2001, and has led various sales and marketing teams in several therapy areas and customer segments. From 2006-2010, he served as Vice President, Strategic Pricing, Contracting and Payer Marketing. Prior to joining GSK, Mr Millar spent 11 years with Procter & Gamble, where he held a variety of positions, including country manager for the UK, Netherlands and Ireland. Throughout his career, Mr Millar has gained extensive sales and marketing experience working with providers, hospitals, health systems, and public and private payers.

Reynold W. (Pete) Mooney

Reynold W. (Pete) Mooney

Global Managing Director, Life Sciences and Health Care
Deloitte

Reynold W. (Pete) Mooney is a senior strategy consulting principal and is currently the Global Managing Director for the Life Sciences and Health Care industry group for Deloitte Touche Tohmatsu Limited (Deloitte). In this role, he is responsible for building practice capability around the world, ensuring consistent service offerings across lines of business, and works closely with Deloitte’s network of member firms in serving clients, governments, Ministries of Health, NGOs, and other constituencies. He is also a principal in Deloitte’s US member firm. Mr Mooney is consulted frequently on global health issues and by pharmaceutical, biotechnology, medical device and other companies that supply the industry. He is a frequent speaker and author on industry topics. Over the course of his thirty-five year career with Deloitte member firms, he has served a number of very significant client relationships across a diverse set of issues, industry sectors, geographies and cultures. A manufacturing professional by background, his approach to strategy is grounded in solid operations management concepts. He gravitated to the life sciences sectors while working with several European chemicals conglomerates in the early 1990s, and currently works with a diverse set of leading life sciences and health care clients globally in both the public and private sectors.

Mr Mooney received a BA from Washington & Jefferson College, where he currently serves as a Trustee, and an MBA. from the Katz School of Business, University of Pittsburgh.

Dr Joshua  Ofman

Dr Joshua Ofman

Senior Vice President, Global Value and Access
Amgen

Joshua Ofman is currently the Senior Vice President of Global Value, Access & Policy at Amgen. He received his advanced medical training in Gastroenterology from UCLA and his Health Services Research training from the RAND/UCLA/VA program. He formally was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

Jay  Olshansky

Jay Olshansky

Professor
University of Illinois at Chicago

Jay Olshansky is currently a Professor in the School of Public Health at the University of Illinois at Chicago and Research Associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine. The focus of his research to date has been on estimates of the upper limits to human longevity, exploring the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases. Dr Olshansky is on the Board of Directors of the American Federation of Aging Research and is the first author ofThe Quest for Immortality: Science at the Frontiers of Aging (Norton, 2001). Dr Olshansky received his PhD in Sociology at the University of Chicago in 1984.

Dr John  Rowe

Dr John Rowe

Professor
Columbia University Medical Center

Dr John Rowe is a Professor in the Department of Health Policy and Management at the Columbia University Mailman School of Public Health. Previously, from 2000 until his retirement in late 2006, Dr Rowe served as Chairman and CEO of Aetna, Inc., one of the nation's leading health care and related benefits organizations. Before his tenure at Aetna, from 1998 to 2000, Dr Rowe served as President and Chief Executive Officer of Mount Sinai NYU Health, one of the nation’s largest academic health care organizations. From 1988 to 1998, prior to the Mount Sinai-NYU Health merger, Dr Rowe was President of the Mount Sinai Hospital and the Mount Sinai School of Medicine in New York City.

Before joining Mount Sinai, Dr Rowe was a Professor of Medicine and the Founding Director of the Division on Aging at the Harvard Medical School, as well as Chief of Gerontology at Boston’s Beth Israel Hospital. He was Director of the MacArthur Foundation Research Network on Successful Aging and is co-author, with Robert Kahn, Ph.D., of Successful Aging (Pantheon, 1998). Currently, Dr Rowe leads the MacArthur Foundation’s Network on An Aging Society.

Dr Rowe was elected a Fellow of the American Academy of Arts and Sciences and a member of the Institute of Medicine of the National Academy of Sciences. He serves on the Board of Trustees of the Rockefeller Foundation and is Chairman of the Board of Overseers of Columbia University’s Mailman School of Public Health. He was Founding Chair of the Advisory Council of Stanford University’s Center on Longevity, a founding Commissioner of the Medicare Payment Advisory Commission (Medpac) and Chair of the board of Trustees of the University of Connecticut.

Dr Michael Severino

Dr Michael Severino

Executive Vice President, Research & Development and Chief Scientific Officer
AbbVie
Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1

fallback

Download the free event brochure

Download now

Agenda - 6th May

  • 8:00am
    Registration and Breakfast
  • 9:00am
    Opening Remarks

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:05am
    At the Cusp? Healthcare and the Future

    Healthcare reform in the US is reaching a new level of maturity, with a growing realization that despite the ebb and flow of political maneuvering and change, reversal is unlikely and reform is here to stay. At this important juncture, what can we ascertain about how reform will transform the healthcare market in the US? Will we succeed in bending the cost curve? Will the US in the longer term move towards a universal, single payer system? Will employers become disengaged from healthcare provision? And what can be said more generally about how healthcare will be transformed in the years ahead? With significant innovations and progress underway in the field of genomics, biotechnology, digital and health technologies and age-related disease research for instance, are we nearing a tipping point of a major transformation of healthcare? Which diseases and health challenges will today’s Millennials face that their parents didn't? Will dealing with the label of pre-clinical disease, for instance, become the major health dilemma for the next generation? As new models and provider of care proliferate, will the patient-doctor relationship become medicine’s fastest fading commodity?

    Dr Troyen Brennan, Chief Medical Officer, CVS Health
    Helen Darling, Strategic Adviser, Former President and CEO, National Business Group on Health
    Malay Gandhi, Managing Director, Rock Health
    Dr John Rowe, Professor, Columbia University Medical School
    Christi Shaw, US Country Head, Novartis, President, Novartis Corporation

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 10:05am
    Pricing and Reimbursement: Surviving and Thriving in a Value Based World

    With the recent launch of Gilead’s Solvadi, a new hepatitis C drug at a cost of $ 84,000 for a 12 week course, a political debate In the US over drug pricing was unleashed, marked by what amounts to a national rebellion against the company and its drug. With the use of such high price specialty drugs expected to rise, and pressure to curtail costs increasing, is the Solvadi case a harbinger of greater scrutiny of drug pricing in the US from payers, politicians and the public? How much it too much? Will companies have to accept lower prices than expected for specialty medicines? Will we see drug rationing with a body such as NICE in the UK, or something comparable, emerging as a gatekeeper for new medicines? Are market forces/prices the only effective way to drive medical innovation? What role could risk sharing and other value based pricing models play?

    Session Keynote: Dr Todd Hobbs, Chief Medical Officer, Novo Nordisk, North America
    Dr Peter Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
    Paul Hudson, President, AstraZeneca US and Executive Vice President, North America, AstraZeneca
    John LaMattina, Senior Partner, PureTech Ventures
    Dr Joshua Ofman, Senior Vice President, Global Value and Access, Amgen

    Moderated by: David Crow, Senior US Business Correspondent, Financial Times

  • 11:05am
    Networking Break
  • 11:25am
    Keynote Interview

    Paul Hudson, President, AstraZeneca US and Executive Vice President, North America, AstraZeneca

  • 11:50am
    Growth and Transformation Strategies at the Intersection of Change: M&A and Beyond

    Anyone witnessing the feverish deal-making that has swept through the global life sciences and healthcare industry recently might conclude that M&A activity has become the dominant force shaping the industry. M&A, however, is just one way forward, as companies respond to change in this dynamic and innovative space. Companies are embracing a variety of approaches including investments in emerging markets, collaborations and partnerships, including with new players outside the healthcare sector in their quest for growth. What forces have been driving M&A, and are they hear to stay? Has recent M&A been opportunistic or ‘retooling for next decade’? Which types of deals will yield the greatest value? To what extent might regulatory and political scrutiny limit the efficiencies that can be achieved in M&A deals? Will we see more deals between big pharma rivals-what are the risk of such deals, and are they set to become commonplace? What are the patient engagement strategies healthcare companies are undertaking to ensure patient are ‘front and centre’ to their business? Where are companies looking for tomorrow’s progressive growth, and what do the ‘bets’ new entrants are placing in the industry tell us about where future growth may come from?

    Session Keynote: Geno Germano, Group President, Global Innovative Pharma Business, Pfizer
    Dr Rodney Hochman, President and CEO, Providence Health & Services
    Dr Jeremy Levin, Chairman, Ovid Therapeutics
    Dame Louise Makin, Chief Executive Officer, BTG plc
    Jamey Millar, Senior Vice President, Managed Markets and Government Affairs, GlaxoSmithKline

    Moderated by: Reynold W. (Pete) Mooney, Global Managing Director, Life Sciences and Health Care, Deloitte

  • 12:50pm
    Lunch

    David Cordani, President and CEO, Cigna Corporation

    Sponsored by:

    Cigna-Corporation_logo[1]

  • 2:00pm
    Aging, Disease and the Secrets of Longevity

    A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending lifespan-or healthspan as it is more appropriately known-but also of studying the link between the processes of aging and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which centenarians could become the norm rather than the exception-when aging could possibly be ‘cured’, resulting in a less crippling and costly burden on the healthcare system. Where is research heading and what have been the strategies behind the companies making a move into this growing field? What new ways might emerge of diagnosing, understanding and addressing the diseases of aging? Given the lack of significant progress in tacking degenerative diseases such as Alzheimer's and Parkinson's to date, what is the case for thinking success is achievable now, and what is timeline for the availability of new anti-aging medicines? What are the practical and philosophical challenges which need to be addressed before the development of ant-aging drugs arrives in earnest? With regards to the here and now business of Alzheimer's, how realistic are the government goals of a disease-modifying medicine by 2025? Will investment incentives and extended patents be made available?

    Aubrey de Grey, Chief Science Officer, SENS Research Foundation 
    Felix Frueh, Chief Scientific Officer, Human Longevity
    Drew Holzapfel, Executive Director, Global CEO Initiative on Alzheimer's Disease
    Jay Olshansky, Professor, University of Illinois at Chicago
    Dr Michael Severino, Executive Vice President, Research & Development and Chief Scientific Officer, AbbVie

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 3:00pm
    The Potential and Perils of Digital Health and Cyber Security

    The wearables craze is well established, health apps are proliferating and big data is becoming a reality. Where next in the convergence of health and digital technology? Do deals such as Novartis-Google and Abbvie-Calico signal that big pharma is waking up to the opportunities and disruptive threats of digital health? One of the unintended consequences of the digitisation of healthcare and increasingly networked connectivity, however, is the heightened risk of cyber-attack compromising the availability, integrity and confidentiality of private health information, with resultant damage to reputation and brand, and the loss of patient goodwill. The healthcare industry was subjected to the largest (43%) of cyber-attacks of any industry in 2013, a 30 % increase in the previous year .Will considerations of cyber security and privacy stop the digital revolution in its tracks? What are the capability gaps of healthcare companies, and how should this challenge be addressed?

    Brian Cincera, Vice President, Global Information Security, Pfizer
    Walter de Brouwer, Founder and CEO, Scanadu
    Pierre-Alexandre Fournier, Co-founder and CEO, Hexoskin
    Jennifer Malatesta, Principal, Deloitte

    Moderated by: David Crow, Senior US Business Correspondent, Financial Times

  • 4:00pm
    Closing Remarks
  • 4:05pm
    Networking cocktail reception

Who Attends?

This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
  • Medical Devices and Diagnostics
  • Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups)
  • Legal Counsel
  • Healthcare IT (Patient records, data, mobile healthcare applications, social media)
  • Regulation

OUR PREVIOUS ATTENDEES INCLUDED:

Aetna
AHIP             
BioPharm Insight            
Blackstone Healthcare Partners
Cigna
Eastern Long Island Hospital
EDventure Holdings
Ernst & Young
GE Healthcare
GSK
Intermountain Healthcare
Mayo Clinic
Memorial Sloan Kettering Cancer Center
North Shore-LIJ Health Center
Novartis
PhRMA
Rivermend Health
Sandoz 
Towers Watson
Verizon Enterprise Solutions

Abbott
AstraZeneca
Berkley Life Sciences
Cardinal Health Canada
Cold Spring Harbor Laboratory
Covance
Edelman
Eli Lilly & Company
Ferring Pharmaceuticals
GNS Healthcare
Interbrand Health
Johnson & Johnson
Medtronic
New York Genome Center
New York State Department of Financial Services
Pfizer
Quest Diagnostics
Sanofi
Takeda Pharmaceuticals 
UK Trade and Investments

fallback

Venue

The Metropolitan Club
One East 60th Street (at Fifth Avenue)
New York 10022

United States of America

Tel: +1 212-838-7400

fallback

Lead Sponsor (1)

Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk-us.com

Luncheon Sponsor (1)

Cigna Corporation (NYSE:CI) and its subsidiaries comprise a global health services and financial company that serves millions of people worldwide through our health, pharmacy, behavioral, dental, disability, life, accident and international products and services. Our mission is to help improve the health, well-being and sense of security of the people we serve.

Supporting Organizations (13)

AdvaMed advocates on a global basis for the highest ethical standards, timely patient access to safe and effective products, and economic policies that reward value creation. AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. Learn more at www.advamed.org.

BioPharm Insight is the definitive guide to the global life sciences community. BioPharm Insight provides clients with an information edge by combining a comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists. More info at: www.biopharminsight.com

Biotechgate is the global lead sourcing database for the Biotech, Pharma and Medtech industries. Identify potential business partners, new leads and benchmark your deals.

  • Over 20,000 Biotech, Pharma and Medtech assets available for licensing
  • Over 50,000 companies including management contacts, products and financing rounds
  • Unique dataset and data management process
  • Small Biotech, Medtech and Pharma companies
  • Collaboration with a worldwide network of over 30 cluster organizations
  • Benchmark license agreements with financial information

CanBiotech is an open innovation platform for the biotechnology and pharmaceutical industries. Source new partners through the CanBiotech portal, participate in our open innovation training workshops in partnership with BioEndeavor and engage CanBiotech and its network of partners to enable open innovation in your organization.

The Galien Foundation is a world healthcare forum that fosters and acknowledges excellence in scientific innovation that improves the state of human health.

The Foundation oversees and directs activities for the Prix Galien USA, an international peer-award that recognizes scientists for their outstanding applied research achievements in improving the human condition through the development of innovative therapies and diagnostics. 

The Health Care M&A Information Source is a comprehensive data source that is devoted to health care mergers and acquisitions for the serious analyst and investor. This publication alerts you to developments in every key segment of the health care services and technology markets, including behavioral health care, biotechnology, eHealth, home health & hospice, hospitals, laboratories, long-term care, managed care, medical devices, pharmaceuticals, physician medical groups, rehabilitation and more. You won’t find more comprehensive information anywhere else. Sign up for a risk-free trial today!

HCPEA is a not-for-profit trade association whose mission is to support the reputation, knowledge, and relationships of the healthcare private equity community.

As the first sector-focused trade association in private equity, HCPEA's 50+ member firms are among the the best known, most respected private equity firms located throughout the United States and Canada. The Association strives to promote a greater understanding of private equity's contribution to the healthcare economy by supporting initiatives that make healthcare an appealing sector for investment, promoting institutional/limited partner investment within the sector, investing in the professional development of our members, and facilitating collaboration between our members and the larger healthcare community.

The International Lawyers Network is an association of 91 high-quality, full-service law firms with over 5,000 lawyers worldwide. The Network provides clients with easily accessible legal services in 67 countries on six continents.

Northeast Business Group on Health is a network of employers, providers, insurers and other organizations working together to improve the quality and reduce the cost of health care in New York, New Jersey, Connecticut and Massachusetts. Our mission is empowering our members to drive excellence in health and achieve the highest value in healthcare delivery and the consumer experience.

PharmaBoardroom is the premier website for C-Level executives, regulators, consultants and vendors working in Healthcare Life Sciences globally. PharmaBoardroom gathers the data, the people and the opinions that matter, and makes market synergies meet. With hundreds of exclusive interviews with shakers and movers of the industry, supplemented by the latest news from global markets, articles, market overviews, and a comprehensive database of the most important companies and business leaders in each key market, PharmaBoardroom is an invaluable resource for those who want to look beyond figures. 

The leading global provider of thought leadership and insight dedicated to the pharma/healthcare industry the pharmaphorum channels bring together news, analysis and expert perspectives from all stakeholders in health, including commercial providers, healthcare professionals and patients. This thought-provoking content keeps the pharmaceutical industry informed and connected, driving collaboration and innovation.

PharmaTelevision® is the groundbreaking online channel for the biopharma industry, featuring interviews with industry leaders, panel discussions, analysis and a life-science news archive. Since 2006, it has rapidly grown and now boasts a global audience of 10,000+ viewers including top industry executives.

PharmaTelevision is produced by professional television industry experts using mobile broadcast studios worldwide as well as its own studio in Oxford, England.

Other PTV channels include the Regional Channel – featuring programmes focusing on the key locations for pharmaceutical and biotech investment and the Financial Channel– featuring interviews with leading life-science investors.

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest life sciences technologies, products and techniques with impartial product reviews, videos, application notes and news articles. Become a member for free today: www.selectscience.net.

CONTACT US

Chrissy McNasby
Registration and General Inquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Tim Powell
Sponsorship Opportunities
Financial Times